WELCOME TO The Biotechnology REPORT
Mayday Healthcare Plc
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
Spotlight Therapeutics | December 01, 2020
Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors.
Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...
Capstan | September 15, 2022
Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with $165 million in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy, combining the power of cell therapy with the precision of genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications.
Capstan’s foundational precision in vivo e...
Gilead and MacroGenics | October 18, 2022
Gilead Sciences, Inc. and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
A leader in the bispecific...
Westlake Village BioPartners | December 15, 2020
Westlake Village BioPartners today announced the launch of two new funds totaling $500 million to build and put resources into promising life sciences organizations with transformative therapeutic technologies.
The first fund, known as Opportunity 1, is $70 million and permits Westlake to contribute extra Series B or later-round capital into promising organizations they incubated or invested into with their original fund, Westlake BioPartners 1 (WBP1). One example is a begin...
Cell and Gene Therapy, Industrial Impact
Cell and Gene Therapy, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE